Browsing Clinical Studies by author "Dearnaley, David"
Now showing items 1-20 of 43
-
A Personalized Clinical Dynamic Prediction Model to Characterize Prognosis for Patients With Localized Prostate Cancer: Analysis of the CHHiP Phase 3 Trial.
Parr, H; Porta, N; Tree, AC; Dearnaley, D; Hall, E (ELSEVIER SCIENCE INC, 2023-08-01)PURPOSE: The CHHiP trial assessed moderately hypofractionated radiation therapy in localized prostate cancer. We utilized longitudinal prostate-specific antigen (PSA) measurements collected over time to evaluate and ... -
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
Murray, J; Griffin, C; Gulliford, S; Syndikus, I; Staffurth, J; et al. (ELSEVIER IRELAND LTD, 2020-01-01)BACKGROUND AND PURPOSE: Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides the opportunity to reduce target volume margins. We introduced IGRT methods using standard (IGRT-S) or reduced (IGRT-R) ... -
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard, G; Murphy, L; Clarke, NW; Cross, W; Jones, RJ; et al. (ELSEVIER SCIENCE INC, 2022-01-29)BACKGROUND: Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 ... -
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
James, ND; Clarke, NW; Cook, A; Ali, A; Hoyle, AP; et al. (WILEY, 2022-08-01)Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis ... -
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; et al. (MASSACHUSETTS MEDICAL SOC, 2017-07-27)BACKGROUND: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a ... -
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Hoyle, AP; Ali, A; James, ND; Cook, A; Parker, CC; et al. (ELSEVIER, 2019-12-01)BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the ... -
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; et al. (OXFORD UNIV PRESS, 2018-05-01)BACKGROUND: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ... -
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; et al. (ELSEVIER SCIENCE INC, 2016-03-19)BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ... -
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
Ahmed, M; Dorling, L; Kerns, S; Fachal, L; Elliott, R; et al. (NATURE PUBLISHING GROUP, 2016-05-10)BACKGROUND: Numerous germline single-nucleotide polymorphisms increase susceptibility to prostate cancer, some lying near genes involved in cellular radiation response. This study investigated whether prostate cancer ... -
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley, D; Syndikus, I; Mossop, H; Khoo, V; Birtle, A; et al. (ELSEVIER SCIENCE INC, 2016-08-01)BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a ... -
Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; et al. (ELSEVIER SCIENCE INC, 2020-04-01)PURPOSE: The CHHiP trial randomized 3216 men with localized prostate cancer (1:1:1) to 3 radiation therapy fractionation schedules: 74 Gy in 37 fractions over 7.4 weeks; 60 Gy in 20 fractions over 4 weeks; and 57 Gy in 19 ... -
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.
Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; et al. (CIG MEDIA GROUP, LP, 2017-10-01)BACKGROUND: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on ... -
Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
Brand, DH; Brüningk, SC; Wilkins, A; Fernandez, K; Naismith, O; et al. (ELSEVIER SCIENCE INC, 2021-06-01)PURPOSE: Changes in fraction size of external beam radiation therapy exert nonlinear effects on subsequent toxicity. Commonly described by the linear-quadratic model, fraction size sensitivity of normal tissues is expressed ... -
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.
Murray, J; Gulliford, S; Griffin, C; Wilkins, A; Syndikus, I; et al. (ELSEVIER IRELAND LTD, 2020-03-01)BACKGROUND AND PURPOSE: The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-volume histograms ... -
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; et al. (AMER MEDICAL ASSOC, 2016-03-01)IMPORTANCE: The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ... -
Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity.
Naismith, OF; Griffin, C; Syndikus, I; South, C; Mayles, H; et al. (ELSEVIER SCIENCE LONDON, 2019-09)AIMS: The CHHiP (Conventional or Hypofractionated High-dose Intensity Modulated Radiotherapy In Prostate Cancer; CRUK/06/016) trial investigated hypofractionated radiotherapy for localised prostate cancer. Forward- (FP) ... -
High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
Kishan, AU; Wang, X; Sun, Y; Romero, T; Michalski, JM; et al. (ELSEVIER, 2022-07-01)BACKGROUND: The relative benefits of radiotherapy (RT) dose escalation and the addition of short-term or long-term androgen deprivation therapy (STADT or LTADT) in the treatment of prostate cancer are unknown. OBJECTIVE: ... -
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins, A; Mossop, H; Syndikus, I; Khoo, V; Bloomfield, D; et al. (ELSEVIER SCIENCE INC, 2015-12-01)BACKGROUND: Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally ... -
Hypofractionation trials and radiobiology of prostate cancer.
Gulliford, S; Hall, E; Dearnaley, D (2017-03) -
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
Staffurth, JN; Haviland, JS; Wilkins, A; Syndikus, I; Khoo, V; et al. (ELSEVIER, 2021-12-15)BACKGROUND: Moderate hypofractionation is the recommended standard of care for localised prostate cancer following the results of trials including Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy ...